Upper Tract Urothelial Carcinoma VL

Primary Chemoablation for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma: The OLYMPUS Trial - Seth Lerner

Details
Seth Lerner, MD, FACS, presents updated information on the United States Federal Drug Administration (FDA) approval of Jelmyto (UGN-101) for low-grade upper tract urothelial carcinoma (LG-UTUC), and the results of the OLYMPUS trial, Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus) . LG-UTUC is rare and previously there were few kidney-sparing options. UGN-101 is a mixture of a ther...

Lancet Oncology OLYMPUS Trial Review: Primary Chemoablation for the Treatment of Low Grade Upper Tract Urothelial Carcinoma

Details
Seth Lerner and Sam Change discuss the recent phase 3 OLYMPUS study, published in The Lancet Oncology. Dr. Lerner was the principal investigator of the single-arm study which investigated the use of thermal-reversible gel mitomycin (Jelmyto) for low-grade upper tract urothelial cancer (UTUC). The study had a 59% complete response rate and thus identified and the FDA approved Jelmyto as a kidney-sp...

Journal Club: The Efficacy and Safety of MitoGel™ (UGN-101) on Ablation of Upper Urinary Tract Urothelial Carcinoma (OLYMPUS) - Zachary Klaassen

Details
Zachary Klaassen, MD, MSc, and Christorpher Wallis, MD, Ph.D., discuss the OLYMPUS study of using UGN-101, a mitomycin-containing reverse thermal gel, for the treatment of Upper Tract Urothelial Carcinoma. The Food and Drug Administration approved mitomycin for adult patients with low-grade upper tract urothelial cancer (LG-UTUC). Efficacy determination was based on OLYMPUS, an ongoing, single-arm...

Developments in Treatment Options for Localized and Advanced Upper Tract Disease - Vitaly Margulis

Details
Vitaly Margulis joins Ashish Kamat in a discussion on the top three developments in upper tract urothelial treatment starting with localized disease and moving onto the more advanced disease. With the difficulty in administering treatment in the upper tract, Dr. Margulis highlights intracavitary therapies, genetic changes that are prevalent in upper tract advanced disease, and the use of systemic...

The OLYMPUS Study: Mitomycin Gel for Low-grade Upper Tract Urothelial Cancer - Seth Lerner

Details
The OLYMPUS trial, which led to the approval of Jelmyto (Mitomycin gel) for low-grade upper tract urothelial cancer (UTUC), is an open-label, single-arm, phase 3 trial that aimed to assess the safety and activity of a non-surgical treatment using instillation of UGN-101, a mitomycin containing reverse thermal gel, a kidney-sparing treatment. In this video interview with Sam Chang, Seth Lerner, the...

Moving the Field Forward, Upper Tract Urothelial Carcinoma, The POUT Study - Alison Birtle

Details
Ashish Kamat invites Alison Birtle to share a review of a Phase III Randomized Trial of Perioperative Chemotherapy versus Surveillance in Upper Tract Urothelial Carcinoma (UTUC) POUT study. The POUT study sought to answer the basic question, does adjuvant chemotherapy reduce the risk of relapse for upper tract urothelial carcinoma (UTUC) patients who've had a potentially "curative," nephroureterec...

Biology and Genomic Distinctions in Metastatic Urothelial Carcinoma and Upper Tract Urothelial Cancers - Andrew Hsieh - Bishoy Faltas - Matthew Galsky

Details
Petros Grivas hosts Matthew Galsky, Bishoy Faltas and Andrew Hsieh in a discussion about their research programs and recent findings that drive closer to providing personalized medicine in the treatments in metastatic urothelial carcinoma and upper tract urothelial cancers. Groundbreaking work is discussed in this podcast and the three platform papers that discuss this evidence in more detail are...

SAUL Trial Data: Real World Experience of Atezolizumab in Carcinomas of the Urinary Tract- Cora Sternberg

Details
Cora Sternberg, MD and Alicia Morgans, MD discuss the SAUL (A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract) trial data which represents the "real world" experience with atezolizumab for the treatment of carcinomas of the urinary tract. The SAUL study enrolled patients that typically would be excluded from clinical trials includ...

Systemic Therapies in Upper Tract Urothelial Carcinoma - Srikala Sridhar

Details
Kala Sridhar provides a state of the-state in the contemporary understanding of upper tract disease, recent clinical trial findings and the impact of those trials on clinical practice treatment. Upper tract urothelial cancer (UTUC) accounts for approximately 5 - 7% of all urothelial cancers. At presentation about 60% of patients demonstrate invasive and/or locally advanced disease compared to abou...

Challenges in the Diagnosis and Treatment of UTUC - Peter Black

Details
Peter Black, MD discusses the challenges in both the diagnosis and treatment of UTUC. First, Dr. Black mentions the difficulty in obtaining adequate tissue for confirmation of diagnosis and to risk stratify patients. Traditionally diagnosis has been made based on imaging alone due to the challenges with obtaining biopsies leading to overtreatment for many patients. Due to the inability to appropri...